Skip to NavigationSkip to content

Former Merck R&D expert joins RedX Pharma board

Published on: 04/01/16

Dr Bernhard Kirschbaum, 57, has been added as a non-executive director at RedX Pharma with immediate effect.

Kirschbaum is a former Merck research and drug development specialist at US pharma giant Merck/Merck Serono, becoming a member of the board of Merck Serono and executive vice-president of global research & early development.

In his last three years, he grew the company's research and development department, doubling the number of phase II assets in this period.

During his career, he has held roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel.

Neil Murray, chief executive of UK-based Redx, says: “He has an outstanding track record and I have no doubt that Redx will benefit from his significant commercial and scientific expertise.”

Redx is focused on improving the characteristics of existing drug classes to create what it hopes are highly effective new medicines.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches